2005年8月
Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of Amyotrophic Lateral Sclerosis
JOURNAL OF THE NEUROLOGICAL SCIENCES
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 235
- 号
- 1-2
- 開始ページ
- 61
- 終了ページ
- 68
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1016/j.jns.2005.04.011
- 出版者・発行元
- ELSEVIER SCIENCE BV
Insulin-like growth factor (IGF)-1 has been shown to have a protective effect on motor neurons both in vitro, and in vivo, but has limited efficacy in patients with amyotrophic lateral sclerosis (ALS) when given subcutaneously. To examine the possible effectiveness of IGF-1 in a mouse model of familial ALS, transgenic mice expressing human: Cu/Zn superoxide dismutase (SOD1) with a G93A mutation were treated by continuous IGF-1 delivery into the intrathecal space of the lumbar spinal cord. We found that the intrathecal administration of IGF-1 improved motor performance, delayed the onset of clinical disease, and extended survival in the G93A transgenic mice. Furthermore, it increased the expression of phosphorylated Akt and ERK in spinal motor neurons, and partially prevented motor neuron loss in these mice. Taken together, the results suggest that direct administration of IGF-1 into the intrathecal space may have a therapeutic benefit for ALS. (C) 2005 Elsevier B.V. All rights reserved.
- リンク情報
- ID情報
-
- DOI : 10.1016/j.jns.2005.04.011
- ISSN : 0022-510X
- Web of Science ID : WOS:000231198400009